The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)

Primary Ciliary Dyskinesia Clinical Trial

— EPIC-PCD  

Official title:

The Ear-Nose-Throat (ENT) Prospective International Cohort of PCD Patients (EPIC-PCD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04611516
• Other study ID #: EPIC-PCD
• Status: Recruiting
• Start date: March 2, 2020
• Est. completion date: December 2030

Study information

• Verified date: October 2023
• Source: University of Bern
• Contact: Myrofora Goutaki, MD-PhD
• Phone: 0041 316315973
• Email: myrofora.goutaki[@]unibe.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Ear-Nose-Throat (ENT) Prospective International Cohort of patients with Primary Ciliary Dyskinesia (EPIC-PCD) is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients keep being managed according to local procedures and guidelines.

Description:

The EPICD-PCD is hosted at the Institute of Social and Preventive Medicine (ISPM) at the University of Bern, Switzerland. Research is performed in close collaboration with all data contributors. This study aims to characterise ENT disease in PCD patients and its association with lower respiratory disease, and to identify determinants of its prognosis. The investigators aim to: 1. Assess the prevalence and severity of sinonasal and otologic symptoms and the frequency and range of signs and physiological findings assessed during standardised ENT physical examination, and describe differences by age; 2. Study the association of sinonasal and otologic disease with lower respiratory disease in PCD patients; 3. Identify determinants of disease course and prognosis of sinonasal and otologic disease in PCD patients. Study design: The EPIC-PCD is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients will keep being managed according to local procedures and guidelines. Patients with PCD are followed regularly at each centre, at 3-month to 6-month intervals. Each patient undergoes a detailed ENT sinonasal and otologic examination by ENT specialists, at minimum once a year, during a programmed follow-up visit. Additional ENT examinations are performed if indicated during in-between follow-up visits. Patients will not be subjected to additional invasive measurements solely for the purposes of the study. What information is collected: The study collect clinical data from patients assessment at regular consultations at the outpatient clinics. For the collection of clinical data, participating centres will use FOLLOW-PCD, a disease-specific form for standardised prospective data collection during routine clinical follow-up of PCD patients. Study database: The EPIC-PCD database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats. How to participate: Centres that wish to participate to the project and contribute data can contact the EPIC-PCD managing centre to sign a data delivery agreement. They then will receive a password to access the online software REDCap and they will be able to enter their data directly. They can also upload follow-up data or add additional patients at a later time point. Funding: The setting up of the EPIC-PCD (salaries, consumables and equipment) was funded by the Swiss National Science Foundation. Data collection and management at each site was funded according to local arrangements. Most participating researchers and data contributors participate in the European Respiratory Society Clinical Research collaboration "Better Evidence to Advance Therapeutic options for PCD" (BEAT-PCD) (https://beat-pcd.squarespace.com/). Infrastructure is provided for free by the University of Bern, where the data are pooled and stored.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 2030
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis of PCD (clinical and test certified)
• Patient must undergo an ENT examination minimum once a year as part of their clinical follow-up Exclusion Criteria: None

Related Conditions & MeSH terms

• Ciliary Motility Disorders
• Dyskinesias
• Kartagener Syndrome
• Primary Ciliary Dyskinesia

Locations

Country	Name	City	State
Switzerland	University of Bern	Bern

Sponsors (11)

Lead Sponsor	Collaborator
University of Bern	Amsterdam UMC, location VUmc, Bicetre Hospital, Centre Hospitalier Intercommunal Creteil, Hacettepe University, Hospital Universitario La Fe, Insel Gruppe AG, University Hospital Bern, Marmara University, Universitaire Ziekenhuizen KU Leuven, University Hospital Southampton NHS Foundation Trust, University of Cyprus

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sinonasal symptoms and signs	Prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring	at baseline
Primary	Course of sinonasal symptoms and signs (year 1)	Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 12 months	at 12 months from recruitment
Primary	Course of sinonasal symptoms and signs (year 2)	Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 24 months	at 24 months from recruitment
Primary	Otological symptoms and signs	Prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge	at baseline
Primary	Course of otological symptoms and signs (year 1)	Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 12 months	at 12 months from recruitment
Primary	Course of otological symptoms and signs (year 2)	Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 24 months	at 24 months from recruitment
Primary	Nasal endoscopy (description of nasal mucosa)	Description of nasal mucosa as seen via nasal endoscopy examination	at baseline
Primary	Nasal endoscopy (changes of nasal mucosa at year 1)	Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 12 months	at 12 months from recruitment
Primary	Nasal endoscopy (changes of nasal mucosa at year 2)	Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 24 months	at 24 months from recruitment
Primary	Nasal endoscopy (nasal polyps)	Prevalence of nasal polyps at baseline	at baseline
Primary	Nasal endoscopy (nasal polyps at year 1)	Changes in prevalence of nasal polyps from baseline to 12 months	at 12 months from recruitment
Primary	Nasal endoscopy (nasal polyps at year 2)	Changes in prevalence of nasal polyps from baseline to 24 months	at 24 months from recruitment
Primary	Sinonasal examination (Lidholdt score)	Lidholdt score at baseline	at baseline
Primary	Sinonasal examination (Lidholdt score at year 1)	Changes in Lidholdt score from baseline to 12 months	at 12 months from recruitment
Primary	Sinonasal examination (Lidholdt score at year 2)	Changes in Lidholdt score from baseline to 24 months	at 24 months from recruitment
Primary	Ear examination (ear discharge)	Prevalence of ear discharge at baseline	at baseline
Primary	Ear examination (ear discharge at year 1)	Changes in prevalence of ear discharge from baseline to 12 months	at 12 months from recruitment
Primary	Ear examination (ear discharge at year 2)	Changes in prevalence of ear discharge from baseline to 24 months	at 24 months from recruitment
Primary	Otoscopy (description of the tympanic membrane)	Description of tympanic membrane as seen via otoscopy examination	at baseline
Primary	Otoscopy (description of the tympanic membrane at year 1)	Changes in the tympanic membrane from baseline to 12 months as seen via otoscopy examination	at 12 months from recruitment
Primary	Otoscopy (description of the tympanic membrane at year 2)	Changes in the tympanic membrane from baseline to 24 months as seen via otoscopy examination	at 24 months from recruitment
Primary	Tympanometry	Results of tympanometry (tympanogram type for both ears) at baseline	at baseline
Primary	Tympanometry (at year 1)	Changes in tympanogram (for both ears) from baseline to 12 months	at 12 months from recruitment
Primary	Tympanometry (at year 2)	Changes in tympanogram (for both ears) from baseline to 24 months	at 24 months from recruitment
Primary	Audiometry	Results of audiometry: type of audiometry and results based on WHO hearing loss grades (for both ears)	at baseline
Primary	Audiometry (at year 1)	Changes in audiometry results from baseline to 12 months	at 12 months from recruitment
Primary	Audiometry (at year 2)	Changes in audiometry results from baseline to 24 months	at 24 months from recruitment